Compass Pathways is preparing to complete its regulatory submission for COMP360, a synthetic psilocybin therapy designed to treat treatment-resistant depression, with the company targeting a rolling FDA submission this quarter and potential launch early next year. The company’s chief executive, Kabir Nath, stated that a measured approach to market entry would be critical, cautioning that poor patient or provider experiences during early stages could damage the emerging psychedelics field more broadly.
Nath highlighted the potential advantages of psilocybin-based treatments compared to conventional antidepressants, noting that the therapy can produce rapid effects through a limited number of supervised administrations rather than requiring daily dosing over weeks. Data from Compass’s Phase 3 trials showed that approximately a quarter of patients experienced clinically meaningful responses after a single COMP360 session, which involves roughly six hours of supervised treatment. Following a second dose administered three weeks later, that response rate increased to about 40 percent, with longer-term data suggesting benefits could persist as long as a year after two or three administrations.
However, Steven Hyman, a Harvard University professor and former National Institute of Mental Health director, raised several scientific concerns about psychedelic treatments. He highlighted the challenge of maintaining blinded trial designs when patients can readily identify the distinctive effects of psychedelic drugs, an issue that contributed to the FDA’s rejection of an MDMA-based therapy from Lykos Therapeutics in 2024. Hyman also questioned whether the psychedelic experience itself is necessary for therapeutic benefit, noting that some companies are exploring compounds designed to produce antidepressant effects without hallucinations.
Additional challenges include determining how much clinical benefit derives from the drugs’ pharmacological properties versus the subjective experience, and establishing the role of psychotherapy in treatment outcomes. Nath stated that Compass deliberately separated psychotherapy from its clinical trials, arguing the company’s focus should be on drug development rather than dictating how physicians provide psychological support. An analysis of recorded sessions found that approximately 80 percent of treatment time involved silence.
Concerns also extend to affordability and access, as treatment costs would encompass not only the drug itself but also several hours of clinical monitoring. Nath indicated that Compass has been working on reimbursement mechanisms and engaging with insurers and government healthcare programs to secure coverage, though he declined to specify pricing relative to Johnson & Johnson’s esketamine treatment Spravato.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI